Vistakon introduces 1-Day Acuvue TruEye CLs

Article

Vistakon Division of Johnson & Johnson Vision Care Inc. has announced the U.S. introduction of 1-Day Acuvue TruEye (narafilcon A) contact lenses.

 

Jacksonville, FL-Vistakon Division of Johnson & Johnson Vision Care Inc. has announced the U.S. introduction of 1-Day Acuvue TruEye (narafilcon A) contact lenses (CLs). 1-Day Acuvue TruEye is now available at some U.S. eyecare professionals’ (ECP’s) offices, with distribution expected to grow in the coming months.

The lens features Hydraclear 1 Technology, which attracts tear film to help maintain the natural ocular environment for all-day comfort, High O2 Consumption, allowing 100 percent corneal oxygen consumption at all points across minus and plus powers, and Class-1 UV-blocking, offering patients the highest level of UV protection in a contact lens, blocking approximately 96 percent of UV-A rays and greater than 99 percent of UV-B rays that reach the lens.

1-Day Acuvue TruEye (narafilcon A) will gradually replace 1-Day Acuvue TruEye (narafilcon B), which was launched in the U.S. in 2010. 

Dave Brown, Vistakon president, said: “Our aim is to quickly transition to 1-Day Acuvue TruEye (narafilcon A), and we will provide doctors with a number of tools to help smooth the conversion process for ECPs and patients. We are confident that 1-Day Acuvue TruEye (narafilcon A) will help doctors make more patients happy, and drive additional patient referrals-the key to practice growth.”

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Recent Videos
Melissa Tawa, OD, FAAO, provides insights to take glaucoma management from reactive to proactive in presentations given at CRU 2025 in Napa, California.
Rachelle Lin, OD, MS, FAAO, details her presentation on inherited retinal diseases at CRU 2025.
Setting the stage in LA: Neda Shamie, MD, on the 19th annual Controversies in Modern Eye Care meeting
Jennifer Li, MD, details a talk she gave alongside Melissa Barnett, OD, FAAO, FSLS, FBCLA, at CRU 2025 in Napa, California.
Deb Ristvedt, DO, details a handful of presentations on glaucoma she gave during CRU 2025 in Napa, California.
Cecelia Koetting, OD, FAAO, DipABO, weighs in on patient assessments, staining pattern insights, and diagnostic tips for patients who may have dry eye disease.
Melissa Barnett, OD, FAAO, FSLS, FBCLA, discusses keratoconus management, diagnosis, and other key insights at CRU 2025.
Cecelia Koetting, OD, FAAO, DipABO, details a talk she gave among optometrists and ophthalmologists at CRU 2025.
Alongside Rachelle Lin, OD, MS, FAAO; Nguyễn, MD, MSc, detailed what treatments are currently available for retinal vascular diseases, including neovascular age-related macular degeneration and diabetic retinopathy.
Dr Paul Karpecki discusses atropine formulation from Sydnexis following NDA acceptance by FDA
© 2025 MJH Life Sciences

All rights reserved.